Kiora Pharmaceuticals (KPRX) Operating Income (2016 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Operating Income came in at -$2.5 million in Q1 2026, down 7.72% YoY from -$2.7 million in Q1 2025, and up 65.66% on a QoQ basis from -$7.3 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Operating Income (2016 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 11 years of Operating Income data on file, last reported at -$2.5 million in Q1 2026.
- Quarterly Operating Income fell 7.72% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.0 million (down 17.83% YoY) and the FY2025 annual result came in at -$12.8 million, down 384.48% from the prior year.
- Operating Income rose to -$2.5 million in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $13.2 million in Q1 2024 to a low of -$7.3 million in Q4 2025.
- A 5-year average of -$2.1 million and a median of -$2.5 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income jumped 789.85% — and 2025, when it tumbled 185.03%.
- Tracing KPRX's Operating Income over 5 years: stood at -$2.6 million in 2022, then increased by 19.6% to -$2.1 million in 2023, then slipped by 21.05% to -$2.6 million in 2024, then plunged by 185.03% to -$7.3 million in 2025, then surged by 65.66% to -$2.5 million in 2026.
- The last three Operating Income figures came in at -$2.5 million (Q1 2026), -$7.3 million (Q4 2025), and -$794437.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | -2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.21 Mn |
| Mar 31, 2026 | -2.51 Mn |
| Dec 31, 2025 | -7.31 Mn |
| Sep 30, 2025 | -794,437.00 |
| Jun 30, 2025 | -2.40 Mn |
| Mar 31, 2025 | -2.33 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -2.54 Mn |
| Mar 31, 2024 | 13.22 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Sep 30, 2023 | -5.92 Mn |
| Jun 30, 2023 | -2.63 Mn |
| Mar 31, 2023 | -1.92 Mn |
| Dec 31, 2022 | -2.63 Mn |
| Sep 30, 2022 | -3.70 Mn |
| Jun 30, 2022 | -2.40 Mn |
| Mar 31, 2022 | -3.57 Mn |
| Dec 31, 2021 | -6.37 Mn |
| Sep 30, 2021 | -3.04 Mn |